Five things for pharma marketers to know: Thursday, March 10, 2016

1. The US Department of Veteran Affairs will start to dispense hepatitis C treatments to all veterans in the health system infected with the virus. The VA plans to spend $1 billion for Gilead Sciences' Sovaldi and Harvoni. An estimated 174,000 veterans enrolled in the VA health system suffer from hepatitis C. (Military Times)

2. Valeant settled a lawsuit with R&O Pharmacy, which was acquired by Philidor Rx Services. The drugmaker had come under fire in recent months for its ties to Philidor. Valeant also convened a committee to investigate its relationship to the specialty pharmacy.

3. What's in a name? For new biotechnology companies, quite a lot, it seems. The fees for using a consulting firm to help them choose a company name can range from $20,000 to $100,000. (Stat)

4. Novartis has increased the price for chronic myeloid leukemia treatment Gleevec, from $26,400 to more than $120,000 for a month's supply of the drug. (WaPo)

5. ICYMI: A former FDA staffer said that patients who received the obesity drug Contrave should be given materials explicitly stating that the drug has no heart benefits. Contrave's manufacturer, Orexigen, released data last year claiming it prevented heart attacks and strokes, but the analysis came from just 25% of the completed study. (Forbes)